NeuroBo Pharma has filed an Investigational New Drug request with the FDA, seeking approval to commence a Phase 1 trial on compound DA-1726 aimed at combating obesity.
Clover Biopharmaceuticals reports positive initial findings from a phase I trial evaluating SCB-219M, an advanced bispecific Fc-fusion TPO-RA protein developed with CHO cell systems, focusing on safety, efficacy, and pharmacokinetics.
Innovent and Xuanzhu Initiate Joint Study Exploring Dual Treatment Approach with Sintilimab (PD-1 Blocker) Plus a New ADC Drug for Progressive Solid Cancers in China.
Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.
Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.
Zealand Pharma has officially presented a request for drug approval to the United States' FDA for their medication glepaglutide, aiming to treat individuals with short bowel syndrome.
Senti Bio has received the green light from the FDA for SENTI-202, aimed at addressing recurring or stubborn blood cancers, such as Acute Myeloid Leukemia.